Search clinical trials for: AS03 Adjuvant

Total 8286 results

PATH
GlaxoSmithKline; Icahn School of Medicine at Mount Sinai; Duke University; Children... and other collaborators

Completed

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

Influenza | Vaccine

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

Influenza, Human

United States, Belgium
Sanofi Pasteur, a Sanofi Company
GlaxoSmithKline

Completed

Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older

COVID-19 (Healthy Volunteers)

United States
GlaxoSmithKline

Recruiting

A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years

Hepatitis B

Germany, United Kingdom, Belgium
National Institute of Allergy and Infectious Diseases...

Completed

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology

Avian Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults

Influenza | Avian Influenza

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline

Completed

Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S (MAL019)

Malaria, Falciparum

United States
SK Bioscience Co., Ltd.
GlaxoSmithKline; Coalition for Epidemic Preparedness Innovations

Active, not recruiting

Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19)

COVID-19 (Healthy Volunteers)

Korea, Republic of
Medicago
Mitsubishi Tanabe Pharma Corporation

Terminated

Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）

SARS-CoV-2 Infection

Japan
National Institute of Allergy and Infectious Diseases...

Completed

Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Mix and Match With AS03

Influenza

United States
SK Bioscience Co., Ltd.
GlaxoSmithKline; International Vaccine Institute; Coalition for Epidemic Preparedness...

Active, not recruiting

Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted With AS03 in Adults Aged 18 Years and Older

COVID-19

Colombia, Nepal
National Institute of Allergy and Infectious Diseases...
Emory University

Completed

Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)

Influenza A Virus, H5N1 Subtype

United States
Erasme University Hospital

Completed

Influenza A/H1N1/2009-adjuvanted Vaccine in Renal Disease Patients

Influenza | Rejection | Decreased Immunologic Activity [PE]

Belgium
Sanofi Pasteur, a Sanofi Company
GlaxoSmithKline

Active, not recruiting

Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older (VAT00002)

COVID-19

Honduras, United States, Australia, France, Kenya, Mexico, New Zealand, Panama, Spain, United Kingdom
GlaxoSmithKline

Active, not recruiting

Safety and Immunogenicity of Different Formulations of Monovalent Influenza A/Astrakhan/3212/2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults

Influenza, Human

United States
Clover Biopharmaceuticals AUS Pty Ltd

Completed

SCB-2019 as COVID-19 Vaccine

COVID-19

Australia
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Vaccination With and Without AS03: Systems Biology Analysis

Influenza

United States
University Health Network, Toronto
Princess Margaret Hospital, Canada

Completed

Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy

Lymphoma | Multiple Myeloma | Influenza A Virus, H1N1 Subtype

Canada
National Institute of Allergy and Infectious Diseases...

Withdrawn

CSL H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations

Influenza
LimmaTech Biologics AG
GlaxoSmithKline

Completed

Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V)

Klebsiella Pneumoniae Infection

Germany
GlaxoSmithKline

Completed

A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older

Influenza, Human

United States
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults

Dengue

United States
SK Bioscience Co., Ltd.
GlaxoSmithKline; International Vaccine Institute; Coalition for Epidemic Preparedness...

Completed

Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)

Covid19

Thailand, Korea, Republic of, New Zealand, Philippines, Ukraine, Vietnam
Tang-Du Hospital

Recruiting

Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC

Carcinoma, Non-Small-Cell Lung | Neoplasm, Residual | Circulating Tumor DNA | Next-Generation Sequencing | Chemotherapy, Adjuvant

China
Korea University Guro Hospital
Korean Center for Disease Control and Prevention

Active, not recruiting

Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)

COVID-19 (Healthy Volunteers)

Korea, Republic of
U.S. Army Medical Research and Development Command
GlaxoSmithKline; Walter Reed Army Institute of Research (WRAIR)

Completed

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico) (DPIV-002)

Dengue Fever

Puerto Rico
Affiris AG

Completed

Safety and Tolerability of AFFITOPE AD03 (MimoVax)

Alzheimer's Disease

Austria
National Institute of Allergy and Infectious Diseases...

Completed

Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly

Influenza Immunisation | Avian Influenza

United States
Attralus, Inc.

Completed

A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis (AT03-001)

Amyloidosis; Systemic

United States
Suzhou Raymon Pharmaceuticals Company, Ltd.
WuXi Clinical

Active, not recruiting

RMP-A03 Ocular Suspension in Patients With Pterygium

Pterygium

United States
GlaxoSmithKline

Completed

Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.

Infections, Papillomavirus

Belgium, United States
National Institute of Allergy and Infectious Diseases...

Completed

2017 A/H7N9 IIV Revaccination

Influenza Immunisation | Avian Influenza

United States
GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults.

Tuberculosis (TB)

Belgium
National Institute of Allergy and Infectious Diseases...
Johns Hopkins University; PPD; Sanofi Pasteur, a Sanofi Company

Active, not recruiting

COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study (CPAT-SG)

COVID-19 | Kidney Transplant

United States
National Institute of Allergy and Infectious Diseases...

Completed

H7N9 Mix and Match With AS03 and MF59 in Healthy Adults

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant

Influenza A Virus, H7N9 Subtype

United States
GlaxoSmithKline

Active, not recruiting

A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults

Cytomegalovirus Infections

United States
GlaxoSmithKline

Active, not recruiting

A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes

Herpes Simplex

Germany, United States, Belgium, Canada, Spain, United Kingdom, Estonia, Australia
National Institute of Allergy and Infectious Diseases...

Completed

Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations

Influenza

United States
Biomedical Advanced Research and Development Authority
Rho, Inc.

Completed

Panblok H7 Vaccine Adjuvanted With AS03 or MF59

Influenza, Human

United States
University Hospital, Toulouse

Completed

NEURodevelopmental Outcome After Persistent Pulmonary Hypertension Of the Newborn (NEUROPHON)

Persistent Pulmonary Hypertension of the Newborn

France
GlaxoSmithKline

Completed

Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years

Infections, Papillomavirus

Korea, Republic of
Immune Response BioPharma, Inc.
cro

Unknown

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis

Multiple Sclerosis

United States
Epimmune

Unknown

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years

Infections, Papillomavirus

Hong Kong
University of Maryland, Baltimore
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

Prostate Cancer
National Cancer Institute (NCI)

Terminated

Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma

Renal Cell Carcinoma

United States
University Hospital, Ghent

Completed

Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®) (HPVXneutra001)

Infection With Human Papillomavirus

Belgium
University of Oxford
European and Developing Countries Clinical Trials Partnership (EDCTP); Kenya...

Completed

A Study to Determine if a New Malaria Vaccine is Safe and Induces Immunity Among Kenyan Adults, Young Children and Infants

Malaria,Falciparum

Kenya

Search clinical trials for: AS03 Adjuvant

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations